Page 3,610«..1020..3,6093,6103,6113,612..3,6203,630..»

Stem cells treatment used by Sydney doctor Ralph Bright ‘untested’ by clinical trials

Posted: Published on September 17th, 2014

ABC Ralph Bright harvests stem cells using the liposuction. Serious questions have been raised about a stem cell doctor working in Western Sydney who charges $9,000 per procedure and uses methods that are untested by clinical trials. An investigation by the ABC's 7.30 program has revealed that Dr Ralph Bright bought his liposuction-based technology from an American company. The US company is now the subject of a multi-million dollar fraud action, which has revealed the cells being marketed as live were in fact dead. Dr Bright, of Macquarie Stem Cells, is a former GP and self-taught cosmetic surgeon. He has been working with stem cells for four years, treating more than 400 patients, including the late model Charlotte Dawson, cricketer Geoff Lawson and Olympic volleyballer Kerri Pottharst. Dr Bright has licensed his methods to other practitioners around the country and because they use the patients' own cells he is not regulated by the Therapeutic Goods Administration (TGA). Stem cells are often hailed as a miracle cure, but the nation's top stem cell scientists are warning that buyers should beware of these sorts of procedures, which are yet to be subjected to clinical trials. Professor of Stem Cell Science at the … Continue reading →

Posted in Cell Therapy | Comments Off on Stem cells treatment used by Sydney doctor Ralph Bright ‘untested’ by clinical trials

West Tennessee Heart and Vascular Center Earns Highest Award from American College of Cardiology

Posted: Published on September 17th, 2014

Jackson, TN (PRWEB) September 16, 2014 The West Tennessee Heart and Vascular Center at Jackson-Madison County General Hospital has achieved the highest award offered by the American College of Cardiology for high-risk heart attack patient treatment. The ACTION Registry-GWTG Platinum Performance Achievement Award was bestowed only to those hospitals that maintained a performance measure score of 90 percent or better in the treatment of acute myocardial infarction (heart attack) patients for eight consecutive quarters, ending in the last quarter of 2013. West Tennessee Heart & Vascular Overall Performance Composite 99.3% STEMI Performance Composite 99.3% NSTEMI Performance Composite 99.3% Discharge Performance Composite 99.3% STEMI is the abbreviation for an ST-elevation myocardial infarction. A STEMI heart attack is recognized by a test called an electrocardiogram that records the electrical activity of your heart. NSTEMI is a shorthand term for non-ST-elevation myocardial infarction. These types of heart attacks are often abbreviated as NSTEMI. While they may not be as serious as the STEMI heart attack, they are still heart attacks and result in heart muscle death. This is the third major quality recognition West Tennessee Heart and Vascular Center has received this year. Earlier the hospital received national recognition for its echocardiography services, … Continue reading →

Posted in Cardiology | Comments Off on West Tennessee Heart and Vascular Center Earns Highest Award from American College of Cardiology

3 Hot Ways to Play the Biotechnology Bonanza

Posted: Published on September 17th, 2014

By Susan J. Aluise, Aviation, Auto & Transportation Writer Just when we thought the biotechnology rally was taking a breather, many biotech stocks got a second wind and thats good news for growth investors. Gaining exposure to the biotechnology sector makes sense for most investors but the big question isnt whether you play the biotech boom, but how you play it. PLUS: Kellogg - Boring-but-Awesome Dividend Stock Lets be clear: biotech stocks are the epitome of volatile, high-beta securities. While the NASDAQ Biotechnology Index is up 18% year-to-date, it has been a wild ride: up 21% from January to late February, down 21% from February to mid-April and up 24% since then. Why do biotech stocks suffer such extreme fits and starts? Simply put, biotechnology is a big bet on highly promising, but extremely uncertain, new treatments created from living organisms like viruses, bacteria, DNA or other molecules. The lions share of biotech drugs flame out in early-stage testing and only 40% of the drugs that clear the final stage of testing receive FDA approval. That said, here are three hot ways to play the surging biotechnology sector now: An individual biotech stock, an exchange-traded fund (ETF) and a mutual … Continue reading →

Posted in Biotechnology | Comments Off on 3 Hot Ways to Play the Biotechnology Bonanza

9th Grade Biology: Cell Organelles – Rough & Smooth Endoplasmic Reticulum – Video

Posted: Published on September 17th, 2014

9th Grade Biology: Cell Organelles - Rough Smooth Endoplasmic Reticulum Part 4 of my cell organelle overviews for my 9th grade biology class. Covered the Rough Smooth Endoplasmic Reticulum. Up next: Golgi Apparatus, Vacuoles Lysosomes Watch Intro to cells:... By: Michael Cook … Continue reading →

Posted in Biology | Comments Off on 9th Grade Biology: Cell Organelles – Rough & Smooth Endoplasmic Reticulum – Video

Exascale, Data and Biology | Rick Stevens, Argonne National Laboratory – Video

Posted: Published on September 17th, 2014

Exascale, Data and Biology | Rick Stevens, Argonne National Laboratory The slide deck for this presentation can be viewed here: http://extremecomputingtraining.anl.gov/files/2014/01/Dinner-Talk-Rick.pdf Presented at the Argonne Training Program on Extreme-Scale... By: ANL Training … Continue reading →

Posted in Biology | Comments Off on Exascale, Data and Biology | Rick Stevens, Argonne National Laboratory – Video

BIOLOGY 1200 LAB – Video

Posted: Published on September 17th, 2014

BIOLOGY 1200 LAB This is our groups video from the Clemson Experimental Forest Lab. By: Gabrielle Moss … Continue reading →

Posted in Biology | Comments Off on BIOLOGY 1200 LAB – Video

Nanopatch to help WHO battle polio

Posted: Published on September 17th, 2014

The World Health Organisations (WHO) battle against polio has a new weapon after joining forces with Vaxxas, the biotechnology company responsible for developing revolutionary vaccine delivery method the Nanopatch. WHO will undertake a research collaboration with Vaxxas, a start-up company that spun out from The University of Queensland. The collaboration will evaluate Nanopatchs use as a platform for delivery of polio vaccine and WHO may subsequently elect to fund clinical demonstrations. The Nanopatch was invented at UQs Australian Institute for Bioengineering and Nanotechnology (AIBN) by Professor Mark Kendall, and aims to replace traditional needle and syringe vaccine delivery methods with a small patch. It features thousands of small projections designed to deliver the vaccine painlessly to the skin. We are delighted to be collaborating with WHO, applying the Nanopatch to help deliver effective polio vaccines to the areas that need them most, said Professor Kendall, Vaxxas Founder and Chief Technology Officer. This project helps realise key advantages of the Nanopatch over the needle and syringe. While the traditional needle and syringe delivers the vaccine to the muscle, the Nanopatch targets the abundant immune cells under the skin, increasing its effectiveness. Furthermore, the Nanopatch doesnt need to be kept refrigerated to … Continue reading →

Posted in BioEngineering | Comments Off on Nanopatch to help WHO battle polio

human anatomy & physiologi study course 4 – Video

Posted: Published on September 17th, 2014

human anatomy physiologi study course 4 By: Beryl Ahren … Continue reading →

Posted in Anatomy | Comments Off on human anatomy & physiologi study course 4 – Video

Trials and tribulations of stem cell therapy

Posted: Published on September 17th, 2014

Stem cells broke into the public consciousness in the early 1990s, but progress has been slow. Photo: Bloomberg Edgar Irastorza was just 31 when his heart stopped beating in October 2008. A Miami property manager, break-dancer and former high school wrestler, Irastorza had recently gained weight as his wife's third pregnancy progressed. "I kind of got pregnant, too," he said. During a workout one day, he felt short of breath and insisted that friends rush him to the hospital. Minutes later, his pulse flatlined. He survived the heart attack, but the scar tissue that resulted cut his heart's pumping ability by a third. He couldn't pick up his children. He couldn't dance. He fell asleep every night wondering if he would wake up in the morning. Desperation motivated Irastorza to volunteer for a highly unusual medical research trial: getting stem cells injected directly into his heart. "I just trusted my doctors and the science behind it, and said, 'This is my only chance,'" he said recently. Over the past five years, by studying stem cells in lab dishes, test animals and intrepid patients like Irastorza, researchers have brought the vague, grandiose promises of stem cell therapies closer to reality. Stem … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Trials and tribulations of stem cell therapy

Global and China Stem Cell Industry Report 2014-2017 Now Available at ChinaMarketResearchReports.com

Posted: Published on September 17th, 2014

Dallas, TX (PRWEB) September 15, 2014 Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatment of cardiovascular diseases, leukemia (a kind of hematological system disease), nervous system diseases, damage or lesion of liver, kidney and other parenchymal organs, etc. Currently, cord blood bank is the fastest-growing and relatively mature market amid stem cell upstream sectors and even the whole industry chain. In 2005, there were 23 cord blood banks worldwide and in 2013 the figure exceeded 480. Global cord blood stem cell (CBSC) storage companies can be roughly divided into two categories: the ones running in a globalized business model, such as Cryo-Cell International and Esperite (formerly known as Cryo-Save Group), and the others giving priority to regional operation e.g. Zhongyuan Union Stem Cell Bioengineering (VCANBIO), Golden Meditech and LifeCell International. However, the companies mainly engaged in cord blood bank business are currently small in scale, only a few with more than 500,000 clients. Order a copy of this report at http://www.chinamarketresearchreports.com/contacts/purchase.php?name=114908 . The stem cell technology and product research-oriented midstream sector is in its infancy, mostly concentrated in … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Global and China Stem Cell Industry Report 2014-2017 Now Available at ChinaMarketResearchReports.com

Page 3,610«..1020..3,6093,6103,6113,612..3,6203,630..»